AU2018338884A1 - Novel salts - Google Patents

Novel salts Download PDF

Info

Publication number
AU2018338884A1
AU2018338884A1 AU2018338884A AU2018338884A AU2018338884A1 AU 2018338884 A1 AU2018338884 A1 AU 2018338884A1 AU 2018338884 A AU2018338884 A AU 2018338884A AU 2018338884 A AU2018338884 A AU 2018338884A AU 2018338884 A1 AU2018338884 A1 AU 2018338884A1
Authority
AU
Australia
Prior art keywords
compound
methyl
disorder
salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018338884A
Other languages
English (en)
Inventor
Gerard M.P. GIBLIN
David T. Macpherson
Julian Northen
Kalyan VASUDEVAN
Michael Williams
David R. Witty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of AU2018338884A1 publication Critical patent/AU2018338884A1/en
Priority to AU2023202293A priority Critical patent/AU2023202293A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2018338884A 2017-09-28 2018-09-28 Novel salts Abandoned AU2018338884A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023202293A AU2023202293A1 (en) 2017-09-28 2023-04-13 Novel salts

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762564744P 2017-09-28 2017-09-28
US62/564,744 2017-09-28
PCT/US2018/053520 WO2019067961A1 (en) 2017-09-28 2018-09-28 NEW SALTS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023202293A Division AU2023202293A1 (en) 2017-09-28 2023-04-13 Novel salts

Publications (1)

Publication Number Publication Date
AU2018338884A1 true AU2018338884A1 (en) 2020-04-16

Family

ID=65902742

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018338884A Abandoned AU2018338884A1 (en) 2017-09-28 2018-09-28 Novel salts
AU2023202293A Withdrawn AU2023202293A1 (en) 2017-09-28 2023-04-13 Novel salts

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023202293A Withdrawn AU2023202293A1 (en) 2017-09-28 2023-04-13 Novel salts

Country Status (14)

Country Link
US (1) US20200255438A1 (enExample)
EP (1) EP3687533A4 (enExample)
JP (1) JP2020536070A (enExample)
KR (1) KR20200060404A (enExample)
CN (1) CN111343978A (enExample)
AU (2) AU2018338884A1 (enExample)
BR (1) BR112020005992A2 (enExample)
CA (1) CA3074923A1 (enExample)
EA (1) EA202090853A1 (enExample)
IL (1) IL273520A (enExample)
MA (1) MA50669A (enExample)
MX (1) MX2020003741A (enExample)
SG (1) SG11202002200UA (enExample)
WO (1) WO2019067961A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018347349A1 (en) 2017-10-10 2020-04-23 Biogen Inc. Process for preparing spiro derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9334269B2 (en) * 2010-02-17 2016-05-10 Amgen Inc. Carboxamides as inhibitors of voltage-gated sodium channels
TW201348235A (zh) * 2012-05-03 2013-12-01 Novartis Ag 作爲格瑞啉受體促效劑之３－螺環哌啶衍生物
GB201209015D0 (en) * 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds

Also Published As

Publication number Publication date
KR20200060404A (ko) 2020-05-29
CA3074923A1 (en) 2019-04-04
IL273520A (en) 2020-05-31
EA202090853A1 (ru) 2020-08-27
AU2023202293A1 (en) 2023-05-11
EP3687533A4 (en) 2021-01-20
MX2020003741A (es) 2021-01-08
EP3687533A1 (en) 2020-08-05
SG11202002200UA (en) 2020-04-29
MA50669A (fr) 2020-08-05
BR112020005992A2 (pt) 2020-09-29
CN111343978A (zh) 2020-06-26
WO2019067961A1 (en) 2019-04-04
US20200255438A1 (en) 2020-08-13
JP2020536070A (ja) 2020-12-10

Similar Documents

Publication Publication Date Title
US9303032B2 (en) 2-(pyridin-2YL)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulator
US10485801B2 (en) Pyrimidinyl-diazospiro compounds
AU2023202293A1 (en) Novel salts
HK40033385A (en) Novel salts
HK1209423B (en) 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted